SCINTIX® autonomous radiotherapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our platform uses to manage motion and autonomously treat solid tumors of any stage of disease.
Our SCINTIX technology autonomously delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.
Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.
Treating cancer isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.
By combining PET-CT and radiotherapy, we're able to find and treat cancer using emissions created by tumors themselves.
Discover SCINTIX therapy.
See how SCINTIX therapy can play a role
in your cancer program.
X2 platform detects substantially more biologic signal to enable new algorithms that potentially expand SCINTIX autonomous radiotherapy to additional tumor types HAYWARD, Calif., July 16, 2026 — RefleXion Medical, an external beam theranostic oncology company, today announced that clinician researchers from leading institutions will present nine scientific studies featuring the new RefleXion® X2 platform at […]
Meaningful progress across reimbursement, clinical adoption, and product innovation is helping freestanding cancer centers (FSCs) bring SCINTIX® autonomous radiotherapy to patients in their local communities. This momentum reflects the dedication of our partners in freestanding centers and hospital outpatient departments who are committed to expanding access to advanced cancer care close to home. Payer Progress: Establishing Fair Medicare Reimbursement A […]
Let us tell you more.
Contact UsStay up to date.
Sign Up